Skip to content
Menu

JP Morgan Maintains Overweight on Adarx Pharmaceuticals, Lowers Price Target to $36

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Tessa Romero maintains Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight and lowers the price target from $38 to $36.

JP Morgan analyst Tessa Romero maintains Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight and lowers the price target from $38 to $36.

Read at benzinga.com

← All stock news